PlexusDx Precision Peptide Genetic Test ($99 add-on) identifies genetic variants in GLP1R and other peptide pathways that influence how quickly your body processes semaglutide
Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should be counselled about this risk Patient safety advice for those using GLP-1 receptor agonists includes: Report persistent nausea, vomiting, or abdominal pain to your GP promptly Stop treatment and seek urgent medical care if you develop severe, persistent abdominal pain that may suggest pancreatitis Maintain adequate hydration, especially during initial treatment and if experiencing vomiting or diarrhoea Monitor for signs of gallbladder problems (sustained upper right abdominal pain, fever, jaundice) Patients with diabetes should monitor blood glucose levels closely, particularly when starting treatment or adjusting doses Inform healthcare providers of all medications to assess interaction risks Report suspected side effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app Pregnant women or those planning pregnancy should not use GLP-1 receptor agonists
In soybean, leaves and seeds contain 50- to 200-fold and 135-fold more homoglutathione than glutathione, respectively (Matamoros et al., 1999)
Branded medications receive FDA oversight, ensuring quality control, consistent dosing, and proven safety profiles, thereby offering trust in your treatment
